MA-022s

MA-022s is a preclinical-stage synthetic lipopeptide being developed by AecorBio for the treatment of steroid-resistant asthma and eosinophilic esophagitis (EoE). As a Toll-like receptor 2/6 (TLR2/6) agonist, MA-022s is designed to modulate the immune environment by inducing a Th1-type cytokine response. This mechanism aims to rebalance the immune system and suppress the Th2-driven allergic inflammation that underlies these respiratory and gastrointestinal conditions, particularly in patients who do not respond adequately to standard corticosteroid therapy. The drug is part of AecorBio's proprietary lipopeptide platform, which focuses on targeted immune modulation to address unmet needs in chronic inflammatory diseases.